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The current paradigm for antibiotic management in
critically ill patients is to initiate broad-spectrum therapy
followed by de-escalation based on microbiological
results. Routine screening cultures may allow better
targeting and reduce unnecessary exposure to
antibiotics.similar proportions in their analysis, whereas most previ-The primary goal of active surveillance cultures (ASC) is
to guide preventive strategies to avoid transmission of
multidrug-resistant bacteria, by identifying carriers and
implementing or maintaining isolation and contact pre-
cautions when indicated. ASC may also be used to pre-
dict infection with multidrug-resistant bacteria in septic
patients and better tailor antimicrobial therapy, especially
for ventilator-associated pneumonia (VAP), as suggested
in a previous issue of Critical Care by a group of investi-
gators in Ghent [1].
De Bus and colleagues analyzed 113 episodes of hospital-
acquired pneumonia (HAP), including 52 VAP episodes, to
examine whether a strategy based on ASC performed better
than a guideline-based strategy derived from the American
Thoracic Society/Infectious Diseases Society of America
guideline [2] and adapted to their local epidemiology.
There are three distinctive features of this study [1].
First, the authors derived the prescription algorithms
subsequently tested from a previous analysis of 100 epi-
sodes of pneumonia; although few details are provided
on their construction, the algorithms were intended to
provide >85% adequate antimicrobial coverage while
avoiding overtreating patients with unnecessarily broad-
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months following its publication. After this time, t
(http://creativecommons.org/licenses/by/4.0), whi
the original work is properly credited. The Creativ
publicdomain/zero/1.0/) applies to the data madSecond, De Bus and colleagues compared both the
appropriateness and spectrum of the actual antibiotic
prescriptions with that of regimens that would have been
administered according to one or the other algorithm-
based strategies, using a scale to grade the spectrum of
antibiotics prescribed, from narrower spectrum to broader
spectrum.
Third, the authors included both HAP and VAP in
ous studies have focused on VAP [3-5] or nosocomial
bloodstream infection [6,7]. However, the latter is both a
strength and a weakness. Applying ASC to pneumonia
in nonventilated patients is of potential interest; how-
ever, the microbiologic features of HAP may differ from
those of VAP, and obtaining ASC in these patients (espe-
cially respiratory tract cultures) is more difficult. Indeed,
recent (2 to 5 days) respiratory tract samples to target
therapy were available in 63 (56%) of all 113 episodes
and were positive in 43 (38%) cases; these samples would
have guided therapy in 31/52 (60%) episodes of VAP, but
in only 12/61 (20%) episodes of HAP [1].
Although the authors did not stratify their analysis
according to HAP or VAP cases, it can be inferred that
most HAP (non-VAP) episodes were included in the
subgroup of the ASC-based strategy where positive ASC
from the respiratory tract dating more than 5 days earlier
or from other sites were available (n = 70), rather than
from recent respiratory tract samples that are known to
more accurately predict the etiology of subsequent
pneumonia [8]. In this subgroup, positive samples were
available for 28 (40%) episodes, which led to upgrading
the antibiotic regimen in 13 (19%) cases and to increasing
the appropriateness of therapy by 10% (from 79 to 88%).
ASC therefore seemed to help narrow the spectrum in
VAP episodes, but to broaden the spectrum in HAP
(non-VAP) episodes.
It is noteworthy that De Bus and colleagues found no
difference in the appropriateness of therapy when com-
paring the two (theoretical) algorithm-based strategiesLtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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ever, treating physicians were aware of the results of
ASC and were probably influenced to some extent by
them, given the longstanding tradition of using ASC at
this center [3,7,9].
Also apparent from this study is that the standard
guideline-based approach to therapy, even when adapted
to the local epidemiology, often results in broader-
spectrum therapy than required. As discussed above,
this may be due in large part to the high proportion of
patients with HAP (non-VAP) in this study, consistent
with a number of recent studies showing that the cri-
teria for suspected infection with multidrug-resistant
bacteria in patients with HAP or healthcare-associated
pneumonia are nonspecific, at least when applied to
European populations [10-12].
Given the higher proportion of appropriate and narrower-
spectrum therapy with ASC than with the guideline-
based approach, should ASC become routine practice
in our ICUs? Clearly, a randomized trial – preferably a
crossover cluster-randomized study – is now needed to
answer this question. This trial would compare a strategy
including ASC as described by De Bus and colleagues with
the standard of care approach, based on empirical therapy
according to the physician’s best judgment accounting
for prior antibiotic exposure, local epidemiology and the
patient’s individual risk factors, followed by de-escalation
[5,13]. The trial should examine patient-centered out-
comes, appropriateness of antibiotics, and overall anti-
biotic exposures. A formal cost-effectiveness of this approach
is also needed, since routinely obtaining thrice-weekly
urinary and sputum or endotracheal aspirate cultures in
addition to weekly oral, nasal, and rectal swab cultures, as is
performed in Ghent, bears substantial costs. Finally, routine
surveillance respiratory or urine cultures may also incite
physicians to initiate therapy for colonization rather than
for infection, and eventually increase the – microbiologically
appropriate, but unnecessary – antibiotic exposure of ICU
patients.
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